Karyopharm Therapeutics Inc. (KPTI) Stock Rating Upgraded by Zacks Investment Research
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm currently has a $11.00 price objective on the stock. Zacks Investment Research’s price target indicates a potential upside of 9.24% from the stock’s current price.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Other equities research analysts have also recently issued reports about the company. Wedbush restated an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th. Canaccord Genuity set a $20.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 6th. HC Wainwright began coverage on Karyopharm Therapeutics in a research report on Thursday, August 18th. They set a “buy” rating and a $15.00 target price on the stock. Jefferies Group upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $9.00 to $12.00 in a research report on Tuesday, August 30th. Finally, S&P Equity Research dropped their target price on Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $15.47.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.07 on Friday. The firm’s 50-day moving average price is $8.73 and its 200 day moving average price is $8.26. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.41. The company’s market capitalization is $415.32 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.12. Equities analysts predict that Karyopharm Therapeutics will post ($3.00) EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Wellington Management Group LLP raised its position in Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock worth $11,323,000 after buying an additional 1,096,029 shares during the period. Baker BROS. Advisors LP acquired a new position in Karyopharm Therapeutics during the third quarter worth $2,111,000. New Leaf Venture Partners L.L.C. raised its position in Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock worth $1,496,000 after buying an additional 210,721 shares during the period. Vanguard Group Inc. raised its position in Karyopharm Therapeutics by 18.5% in the second quarter. Vanguard Group Inc. now owns 816,444 shares of the company’s stock worth $5,478,000 after buying an additional 127,714 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Karyopharm Therapeutics by 29.2% in the second quarter. JPMorgan Chase & Co. now owns 361,979 shares of the company’s stock worth $2,428,000 after buying an additional 81,773 shares during the period. 55.99% of the stock is currently owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.